Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914582 | 0.91 | NPC1 (0.84) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL29214224 | 0.91 | NPC1 (0.84) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL18941215 | 0.86 | NPC1 (0.75) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL18941235 | 0.86 | NPC1 (0.75) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL4761937 | 0.85 | NPC1 (1.00) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL31156451 | 0.85 | NPC1 (1.00) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL13483892 | 0.83 | NPC1 (0.71) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL1663482 | 0.83 | NPC1 (0.71) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL28435041 | 0.83 | NPC1 (0.74) | NPC1RAB9AESR1MAPTMAOA | |
| SCHEMBL3199345 | 0.83 | NPC1 (0.74) | NPC1RAB9AESR1MAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116875475-A | Yeast strain for high-yield cannabinoid synthesis precursor, construction method and application thereof | 森瑞斯生物科技(深圳)有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-114171132-A | Fatigue stress resistant absorbing layer mix proportion design method | 北京工业大学 | 2022-03-11 | — | — | CN | claimed |
| US-20260084095-A1 | Hydrophobic Alkyl-Ester Physical Solvents for CO2 Removal from H2 Produced from Synthesis Gas | US ENERGY (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3784232-B1 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4676912-A2 | COMPOUNDS, COMPOSITIONS, AND METHOD OF INHIBITING TAU PROTEIN AND ALPHA-SYNUCLEIN AGGREGATION | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3977114-B1 | ULTRASOUND SUB-SURFACE PROBE MICROSCOPY DEVICE AND CORRESPONDING METHOD | TNO (NL) | 2025-08-13 | — | — | EP | disclosed |
| CN-112955141-B | Improved method for inducing tissue regeneration and senescent cell lysis in mammalian cells | AGEX治疗公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114364265-B | Flavanone derivatives and their use as sweetness enhancers | 弗门尼舍有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024251921-A1 | ANTHRACYCLINES | ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC (NL) | 2024-12-12 | — | — | WO | disclosed |
| US-12130258-B2 | Ultrasound sub-surface probe microscopy device and corresponding method | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2024-10-29 | — | — | US | disclosed |
| WO-1998046570-A1 | SUBSTITUTED HETEROAROMATIC 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| CN-1184425-A | 5-substituted-3- (1,2,3, 6-tetrahydropyridin-4-yl) -and 3- (piperidin-4-yl) -1H-indoles, 5-HT1FAgonists | LILLY CO ELI (US) | 1998-06-10 | — | — | CN | disclosed |
| EP-0832650-A2 | Use of serotonin 5-HT1F agonists for the prevention of migraine | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998011895-A1 | A METHOD FOR THE PREVENTION OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0824917-A2 | Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1998006402-A1 | TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS | ELI LILLY AND COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| US-5708008-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1996029075-A1 | 5-SUBSTITUTED-3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)- AND 3-(PIPERIDIN-4-YL)-1H-INDOLES: NEW 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1996-09-26 | — | — | WO | disclosed |
| EP-0733628-A1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | NPC1 51/4885RAB9A 2407/4885ESR1 1375/4885 |
| US-20260084095-A1 | Hydrophobic Alkyl-Ester Physical Solvents for CO2 Removal from H2 Produced from Synthesis Gas | SCD, ELOVL3, ACAD10 | NPC1 625/4885RAB9A 3921/4885ESR1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.